Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis
Crenigacestat 是一种选择性 NOTCH1 抑制剂，可通过阻断 VEGFA/DLL4/MMP13 轴来减缓肝内胆管癌进展
阅读：10
作者：Serena Mancarella, Grazia Serino, Francesco Dituri, Antonio Cigliano, Silvia Ribback, Jingxiao Wang, Xin Chen, Diego F Calvisi, Gianluigi Giannelli
Conclusion
We have developed and validated a new iCCA PDX model to test in vivo the activity of LY3039478, demonstrating its inhibitory role in Notch-dependent angiogenesis. Thus, the present data provide new knowledge on Notch signaling in iCCA, and support the inhibition of the Notch cascade as a promising strategy for the treatment of this disease.
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用；引用内容仅为补充信息，不代表本站立场。
2、若认为本页面引用内容涉及侵权，请及时与本站联系，我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容，需注明“来源：[生知库]”并获得授权；使用引用内容的，需自行联系原作者获得许可。
4、投稿及合作请联系：info@biocloudy.com。
